This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Accuray Rolls Out Comprehensive Customer Service Program In Japan

SUNNYVALE, Calif., June 20, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the extension of its industry-leading Emerald Service Program for the TomoTherapy® System, which provides equipment protection and product updates that improve clinical uptime and enhance technology utilization, to customers throughout Japan. As part of its ongoing commitment to strengthening customer service globally, Accuray will now interact directly with TomoTherapy customers in Japan to provide Accuray's higher level service programs in the Japanese radiation oncology market.

"We are dedicated to helping advance radiation oncology treatment in Japan and this is a significant move toward ensuring that our current and future customers throughout the country benefit from the highest quality customer service," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. "We have seen clear traction for both the TomoTherapy and CyberKnife Systems in Japan and believe that by managing the service program directly, we will be able to increase touch points with our customers, hear about their needs first hand and reaffirm their confidence in our products."

Japan is a global leader in the adoption of innovative medical technology and an important market for Accuray. The TomoTherapy System received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) in December 2004, and the first TomoTherapy System was installed in 2005. Both Accuray systems have gained widespread acceptance and presently there are 26 TomoTherapy Systems and 25 CyberKnife® Robotic Radiosurgery Systems in use in Japan.

Previously, Hitachi Medical Corporation provided service and support for TomoTherapy customers in Japan. With the roll out of the Emerald Service Program in Japan, Hitachi Medical Corporation will transfer the regulatory approval and service business to Accuray. The move to take service in house demonstrates Accuray's continued commitment to delivering superior service for TomoTherapy customers and provides new opportunities for growth and further market penetration for both the CyberKnife and TomoTherapy Systems in Japan. Accuray forecasts that the transfer of the service business from Hitachi Medical Corporation to Accuray will drive an increase in service revenue with expected revenue of $5 to 5.5 million dollars over one year.

Accuray and Hitachi Medical Corporation will continue to partner on sales and distribution, enabling Accuray to benefit from Hitachi Medical Corporation's deep territory penetration in the Japan's radiation oncology market. Accuray expects the relationship to also provide opportunities for future growth of the TomoTherapy business globally.

The Emerald Service Program combines best-in-class product service offerings with guaranteed uptime for unparalleled reliability and customer satisfaction. The Emerald Service Program was extended to the TomoTherapy System in the United States in 2011 and the program is now available to customers in Japan.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,067.56 -30.89 -0.18%
S&P 500 2,002.28 -1.09 -0.05%
NASDAQ 4,598.1880 +17.9170 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs